Anticipate generic drug launch
Find generic entry opportunities
Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics|
|Abstract:||Intermediate release nicotinic acid formulations having unique biopharmaceutical characteristics, which are suitable for oral administration once per day as a single dose preferably administered during the evening or at night for treating hyperlipidemia without causing drug-induced hepatotoxicity to such a level that requires the therapy to be discontinued, are disclosed. The intermediate nicotinic acid formulations can be administered as tablets in dosage strengths of, for example, 375 mg, 500 mg, 750 mg and 1000 mg. The 375 mg, 500 mg and 750 mg nicotinic acid tablets of the present invention have a dissolution curve similarity fit factor F.sub.2 of at least about 79, and the 1000 mg nicotinic acid tablets of the present invention have a dissolution curve similarity fit factor F.sub.2 of at least 44.|
|Inventor(s):||Cefali; Eugenio A. (Lauderhill, FL)|
|Assignee:||Kos Pharmaceuticals, Inc. (Miami, FL)|
Patent Claim Types:|
see list of patent claims
|Use; Formulation; Compound; Dosage form; Device;|
Back Citations: 275th percentile
Forward Citations: 0th percentile
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Austria||289197||<disabled in preview>|
|Australia||4751802||<disabled in preview>|
|Australia||6348198||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.